Akcea Therapeutics and Ionis Pharmaceuticals Snag FDA Approval for Tegsedi
Akcea Therapeutics and Ionis Pharmaceuticals Snag FDA Approval for Tegsedi
With Hemlibra, Roche seeks to break into tight hemophilia circle
With Hemlibra, Roche seeks to break into tight hemophilia circle
10 biotechs set to shake up the industry’s top ranks
10 biotechs set to shake up the industry’s top ranks
Alnylam Indicates Phase III Trial Is Successful Thus Far
Alnylam Indicates Phase III Trial Is Successful Thus Far
FDA Approves Eight Novel Drugs in August
FDA Approves Eight Novel Drugs in August
RNAi: The Monoclonal Antibody of the 2020s?
There’s been another milestone in the history of biotech: The world’s first RNAi gene-silencing drug, Alnylam Pharmaceuticals‘ Onpattro, got approved on August 10. That makes 2018 a landmark year. But another … Continue Reading RNAi: The Monoclonal Antibody of the 2020s?
After Alnylam’s solo maiden launch, here comes the tricky bit
14 years after floating on Nasdaq, and with a strategic rebranding as well as $2.4bn of accumulated losses under its belt, Alnylam on Friday achieved its proudest milestone yet: its … Continue Reading After Alnylam’s solo maiden launch, here comes the tricky bit
Taking a Look at Trends in Biotherapeutics
It’s not easy to predict trends in drugs, especially with breakthroughs in immunology and genetic engineering often causing dramatic changes in how biopharma companies approach new drugs. It was pretty obvious four … Continue Reading Taking a Look at Trends in Biotherapeutics
Alnylam Receives FDA Approval for First-Ever RNA Interference Therapeutic
The U.S. Food and Drug Administration (FDA) approved Alnylam Pharmaceuticals’ Onpattro (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults. It is the first and only RNA interference (RNAi) therapeutic … Continue Reading Alnylam Receives FDA Approval for First-Ever RNA Interference Therapeutic
A Roundup of Biopharma Companies that Announced Hiring Trends So Far this Year
Earlier this year, BIO and TEConomy Partners released their 2018 “Investment, Innovation and Job Creation in a Growing U.S. Bioscience Industry” report. It was the eighth biennial report, and focused on the economic progress and the footprint … Continue Reading A Roundup of Biopharma Companies that Announced Hiring Trends So Far this Year
Pharma and Biotech Companies Provide Top Salaries: Survey
It’s no secret there’s money in the pharmaceutical industry. While chief executive officers and c-suite leaders are often noted for receiving large paychecks, some companies also offer lucrative compensation to employees. This … Continue Reading Pharma and Biotech Companies Provide Top Salaries: Survey
FDA Action Alert: DURECT, Vertex, Alnylam, and Regeneron
Now that July is over, the U.S. Food and Drug Administration (FDA) appears to be back in full swing with an ample docket of drug decisions to make. There are four therapeutics with … Continue Reading FDA Action Alert: DURECT, Vertex, Alnylam, and Regeneron
Orphan drugs leveraging new tech promise to cure disease
In an era of unprecedented drug approvals for rare diseases, two late-stage drugs are upping the ante with their promise to cure disease rather than treat symptoms. First to market … Continue Reading Orphan drugs leveraging new tech promise to cure disease
Alnylam Receives Positive CHMP Opinion for ONPATTRO™ (patisiran) for the Treatment of Hereditary Transthyretin-Mediated Amyloidosis in Adults with Stage 1 or Stage 2 Polyneuropathy
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the Committee for Medicinal Products for Human Use (CHMP) has adopted a Positive Opinion recommending marketing authorization … Continue Reading Alnylam Receives Positive CHMP Opinion for ONPATTRO™ (patisiran) for the Treatment of Hereditary Transthyretin-Mediated Amyloidosis in Adults with Stage 1 or Stage 2 Polyneuropathy
The 2018 pipeline report: Aspiring assets to keep an eye on
Looking ahead to 2018, the most promising products in pharma’s pipeline will compete in a landscape that increasingly rewards big risks and places an emphasis on novel mechanisms. That comes with … Continue Reading The 2018 pipeline report: Aspiring assets to keep an eye on
RNA as a Therapy: Reviewing the Future Generation of Therapeutics
You’ve certainly heard about antibodies, peptides and even DNA as therapeutics, but what about RNA? In this review, we paint an overview of what’s up in a young field that … Continue Reading RNA as a Therapy: Reviewing the Future Generation of Therapeutics
